Drug decision

The “potentially life-saving” immunotherapy drug pembrolizumab is now recommended for some people with early triple negative breast cancer in England and Wales.

The National Institute for Health and Care Excellence (NICE) has recommended zanubrutinib (Brukinsa) as an option for treating some people…

NICE does not recommend olaparib (Lynparza) for people with a type of advanced prostate cancer, as the treatment is not deemed cost-effective

A targeted cancer drug has been approved to treat some people with breast cancer that has a high-risk of returning.

Ibrutinib, a drug used to treat Waldenstrom’s macroglobulinaemia, is not being recommended by the National Institute for Health and Care Excellence in England

Sacituzumab govitecan (Trodelvy) is not being recommended by NICE for use in England as a treatment for some people with triple-negative breast cancer.

Hope for patients with early-stage lung cancer as new treatment approved for use on NHS England.

The targeted drug olaparib has been approved for some people with a type of advanced prostate cancer on the NHS in Scotland.